The Ottawa Hospital's Biotherapeutics Manufacturing Centre Rebrands as Boreal Biomanufacturing, Plans Major Expansion
Key Insights
The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) has rebranded as Boreal Biomanufacturing (search), signaling a commitment to becoming a national and global biomanufacturing centre of excellence.
Boreal has developed more than 20 distinct cell- and virus-based products for human clinical trials, including the first made-in-Canada CAR-T therapy (search) and oncolytic cancer (search)-fighting viruses.
In 2029, Boreal will move into the University of Ottawa's Advanced Medical Research Centre (AMRC), expanding its capacity to support more simultaneous viral vector and cell therapy manufacturing programs.
The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC), a pioneering facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials across Canada, the United States, Europe, and Asia, has announced its rebranding as Boreal Biomanufacturing (search) (Boreal). The change marks a major initiative to expand the organization's role as a national and global biomanufacturing centre of excellence.
As an early-phase, non-profit contract development and manufacturing organization (CDMO), Boreal serves both commercial clients and academic researchers. The facility has been instrumental in pioneering the development of oncolytic cancer (search)-fighting viruses and the first made-in-Canada CAR-T therapy (search), while also advancing innovative regenerative stem-cell therapies and viral vectors for gene therapy. Boreal has fostered the development and successful launch of multiple advanced therapy biotech start-ups since its opening in 2006.
Bridging the Translational Divide
Boreal has built a specialized expertise in helping clients bridge what the organization calls the "translational divide" — the critical gap between proof-of-concept of a new advanced therapy and its progression into first-in-human clinical trials.
"For nearly twenty years, our biomanufacturing team has led some of Canada's most important efforts to turn promising ideas into clinically proven therapies," said Dr. Rebecca Auer, Executive Vice-President, Research and Innovation at The Ottawa Hospital. "We have a shared belief here that 'research is care,' which explains why Boreal's role is so important. Right here, right now, we're taking discoveries from commercial and academic researchers and seeing how those innovations can be developed to benefit not only patients at The Ottawa Hospital, but those all over the world."
Strategic Partnerships and Workforce Development
Boreal partners with a number of national networks that accelerate the translational development and progression of advanced therapies, including BioCanRx, the Stem Cell Network, CellCAN, the Canadian Pandemic Preparedness Hub, and the Canadian Biomanufacturing Cooperative. The organization also plays a key role in the Canadian-Led Immunotherapies Collaborative, which developed the first made-in-Canada CAR-T cells.
Additionally, Boreal is home to CanPRIME, the Canadian Partnership for Research in Immunotherapy Manufacturing Excellence — a partnership between The Ottawa Hospital, BioCanRx, and Mitacs, along with Algonquin College and the University of Ottawa — dedicated to training the next generation of biotech manufacturing professionals.
Expansion to the Advanced Medical Research Centre
In 2029, Boreal will move into the University of Ottawa's Advanced Medical Research Centre (AMRC), a seven-storey health sciences hub located near Boreal's current headquarters on The Ottawa Hospital's General Campus. The additional manufacturing suites at AMRC, built with funding from Canada's Biosciences Research Infrastructure Fund and the Ontario Research Fund, will enable Boreal to support even more simultaneous viral vector and cell therapy manufacturing programs.
"Boreal has the right team in place with the right capabilities at the right time," said Eric Lee, General Manager of Boreal. "There's never been more hope for creating better treatments or cures in cancer (search) and other complex diseases, but that hope rests on the ability to manufacture therapies that are safe, effective, and can be scaled to help patients wherever they are. We've proven we have the models to do that, which is why we're expanding both our capacity and our commercial team."
Lee emphasized the unique positioning of the organization: "Everything's right here — the patients, the clinicians, the researchers, the manufacturing capacity. Our clients rely on us to connect all the dots that lead from an idea to an actual trial-ready therapy, and we're uniquely positioned at Boreal to do so."
A Continued Commitment to Innovation
The name "Boreal Biomanufacturing (search)" reflects both the organization's Canadian heritage and its interconnectedness with the broader biotherapy community. Boreal continues to be owned and operated by The Ottawa Hospital, and its expansion is critical to the hospital's goal of reshaping the future of health care.
"The name 'Boreal' is new, but our commitment is stronger than ever," Lee said. "We're still pursuing oncology and rare disease (search) treatments that have never been done before."